Clinical trial
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian…
NCT00046800 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00046800 |
|---|---|
| Title | Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer |
| Official title | A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | OSI Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | OSI-211 (Liposomal Lurtotecan) |
| Enrollment | 80 |
| Start date | Sep 1, 2002 |
| Completion | Mar 1, 2003 |
| First posted | Oct 4, 2002 |
| Last update posted | Oct 20, 2011 |
| Countries | United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: